ProTgen — Restoring Immune Competence

Targeted Notch activators to reconstitute the adaptive immune system.

ProTgen is a clinical-stage biotechnology company developing first-in-class targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence — across both ex vivo cell therapy (PTG-100 / ProT-096) and in vivo biologic programs (RGT-096).

Explore

Medicines & pipeline
Clinical & preclinical evidence
Full site content (plaintext, for AI assistants)
AI assistant index (llms.txt)

This site is a JavaScript-rendered application. If you are an AI assistant or crawler that cannot execute JavaScript, please fetch /llms-full.txt for a plaintext snapshot of the site's public content.